Floatz logo

Dextromethorphan

Advanced Solid Tumor

Mirati Therapeutics Inc.Small moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

1412 Active assets in the Advanced Solid Tumor cohort.

View all 50

Same molecule, other indications

Dextromethorphan is also rated in:

Pseudobulbar Affect (PBA)Dormant
BBB
Indicative ·
75 / 100
View asset →
stroke disorderDormant
BBB
Indicative ·
73 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →